成人腮腺转移癌的分子靶向治疗。
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
机构信息
Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Comprehensive Cancer Center Vienna, Vienna, Austria.
出版信息
Wien Klin Wochenschr. 2021 Jan;133(1-2):32-40. doi: 10.1007/s00508-020-01778-8. Epub 2020 Dec 9.
BACKGROUND
Advanced therapy-refractory parotid gland carcinomas have a poor prognosis with limited therapy options. We used molecular profiling to offer molecular guided therapies to patients with advanced metastatic parotid gland malignancies.
METHODS
In this retrospective analysis we describe the molecular profiling of ten patients diagnosed with therapy-refractory metastatic parotid gland malignancies.
RESULTS
We identified seven genetic aberrations in five patients: two mutations in CDKN2A and one mutation in APC, ATM, TP53, SMARCB1 and FGFR1, respectively. No mutations were detected in five patients. The IHC demonstrated frequent expressions of EGFR and p‑mTOR, as well as PTEN in eight patients. For four fifths (n = 8) of the patients, a targeted therapy was suggested. Eventually, three patients received the targeted therapy recommendation and one patient achieved stable disease for 14 months.
CONCLUSION
A total of eight therapy recommendations were provided. Based on our observations, molecular-guided therapies may be a feasible treatment approach for this rare disease entity.
背景
对于治疗难治性腮腺腺癌，由于治疗选择有限，预后较差。我们使用分子谱分析为晚期转移性腮腺恶性肿瘤患者提供分子指导治疗。
方法
在这项回顾性分析中，我们描述了十位治疗难治性转移性腮腺恶性肿瘤患者的分子谱分析。
结果
我们在五名患者中发现了七个基因异常：CDKN2A 中的两个突变和 APC、ATM、TP53、SMARCB1 和 FGFR1 中的一个突变，分别。五名患者均未检测到突变。IHC 显示八位患者中 EGFR 和 p-mTOR 以及 PTEN 的表达频繁。对于五分之四（n=8）的患者，建议进行靶向治疗。最终，三名患者接受了靶向治疗建议，一名患者疾病稳定 14 个月。
结论
共提出了八项治疗建议。根据我们的观察，分子指导治疗可能是治疗这种罕见疾病实体的可行方法。
Zotero 插件